A Phase 3 interventional study of Etrasimod and Placebo in Ulcerative Colitis, sponsored by Pfizer. Completed at 38 sites in Japan. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-16.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing etrasimod in Colitis, Ulcerative — 3 open to participants now, 5 under way, 2 of them phase 3. etrasimod · Colitis, Ulcerative.
Among the 12 studies testing etrasimod in Colitis, Ulcerative, this one is the 10th largest by enrollment, is one of 2 that started in 2020, is one of 5 in phase 3, and was the 8th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →3 of the 12 studies testing etrasimod in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Australia, Canada and 7 more countries
Ages 2–11
Pfizer · Sites in United States, Japan, Poland and 2 more countries
Ages 12–17
Sir Run Run Shaw Hospital
Ages 18–100
By country, each count listing its studies:
etrasimod: first FDA approval 2023 (VELSIPITY), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 16 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2020.
This study's enrollment of 42 is below the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 195 across the 12 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 12 have an industry lead sponsor. The 4 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
42 studies in Colitis, Ulcerative by Pfizer: 3 open now, 7 under way, 2 of them phase 3. Of 32 finished, 26 (81%) have results posted.
Among the 42 studies in Colitis, Ulcerative by Pfizer, this one is the 20th largest by enrollment of the 24 interventional ones that give a count, is one of 7 that started in 2020, is one of 9 in phase 3, and was the 30th registered.
Pfizer’s Colitis, Ulcerative studies by the year they started, since 2005.
1 of the studies testing etrasimod in Colitis, Ulcerative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07782242Sir Run Run Shaw HospitalComaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UC | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing etrasimod in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 42 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment in adult Japanese participants with moderately to severely active ulcerative colitis (UC). This study is an extension of study APD334-302 (NCT03996369). Participants will continue with the same blinded treatment assigned in Study APD334-302 for a total treatment duration of 52 weeks (12 weeks in Study APD334-302 plus 40 weeks in Study APD334-308).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with moderately to severely active ulcerative colitis (UC) are eligible to enroll into this study if they fulfill all of the following:
Exclusion Criteria:
Participants who meet any of the following exclusion criteria will not be eligible for enrollment into the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Etrasimod
Drug: Placebo
Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks
Also known as: APD334
Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks
Percentage of Participants Achieving Clinical Remission at Week 40 of Study APD334-308
Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \[\>=\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
Time frame: Week 40 of APD334-308
Percentage of Participants Achieving Endoscopic Improvement at Week 40 of Study APD334-308
Endoscopic improvement was defined as an ES \<=1 (excluding friability) at Week 40 of APD334-308 compared with Week 12 of APD334-302. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease); higher score indicated more severe disease.
Time frame: Week 40 of APD334-308
Percentage of Participants Achieving Symptomatic Remission at Week 40 of Study APD334-308
Symptomatic remission was defined as an SF sub-score = 0 (or = 1 with a \>= 1 point decrease from Baseline) and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.
Time frame: Week 40 of APD334-308
Percentage of Participants With Mucosal Healing at Week 40 of Study APD334-308
Mucosal healing was defined as an ES \<= 1 (excluding friability) with histologic remission measured by a Geboes Index score less than \[\<\] 2.0). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system, was a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicated more severe disease.
Time frame: Week 40 of APD334-308
Percentage of Participants, Who Had Not Been Receiving Corticosteroids for ≥ 12 Weeks, Achieving Clinical Remission at Week 40 of Study APD334-308 Among Participants Receiving Corticosteroids at C5041015 (APD334-302) Study Entry
Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \[\>=\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
Time frame: Week 40 of APD334-308
Percentage of Participants Achieving Sustained Clinical Remission
Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \[\>=\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease. A subject with sustained clinical remission is defined as someone who achieved clinical remission at both Week 12 of APD334-302 and Week 40 of APD334-308.
Time frame: Week 40 of APD334-308
| Milestone | Placebo Comparator: Placebo | Experimental: Etrasimod 2 mg |
|---|---|---|
| Started | 14 | 28 |
| Completed | 4 | 18 |
| Not completed | 10 | 10 |
| Withdrew: Disease worsening | 10 | 10 |
| Milestone | Placebo Comparator: Placebo | Experimental: Etrasimod 2 mg |
|---|---|---|
| Started | 14 | 28 |
| Completed | 4 | 18 |
| Not completed | 10 | 10 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Disease worsening | 8 | 10 |
| Withdrew: Adverse event | 1 | 0 |
Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \[\>=\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
| Percentage of participants | Placebo Comparator: Placebo | Experimental: Etrasimod 2 mg |
|---|---|---|
| Percentage of Participants Achieving Clinical Remission at Week 40 of Study APD334-308 | 7.1 | 25.0 |
Endoscopic improvement was defined as an ES \<=1 (excluding friability) at Week 40 of APD334-308 compared with Week 12 of APD334-302. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease); higher score indicated more severe disease.
| Percentage of participants | Placebo Comparator: Placebo | Experimental: Etrasimod 2 mg |
|---|---|---|
| Percentage of Participants Achieving Endoscopic Improvement at Week 40 of Study APD334-308 | 7.1 | 35.7 |
Symptomatic remission was defined as an SF sub-score = 0 (or = 1 with a \>= 1 point decrease from Baseline) and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.
| Percentage of participants | Placebo Comparator: Placebo | Experimental: Etrasimod 2 mg |
|---|---|---|
| Percentage of Participants Achieving Symptomatic Remission at Week 40 of Study APD334-308 | 7.1 | 39.3 |
Mucosal healing was defined as an ES \<= 1 (excluding friability) with histologic remission measured by a Geboes Index score less than \[\<\] 2.0). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system, was a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicated more severe disease.
| Percentage of participants | Placebo Comparator: Placebo | Experimental: Etrasimod 2 mg |
|---|---|---|
| Percentage of Participants With Mucosal Healing at Week 40 of Study APD334-308 | 7.1 | 28.6 |
Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \[\>=\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
| Percentage of participants | Placebo Comparator: Placebo | Experimental: Etrasimod 2 mg |
|---|---|---|
| Percentage of Participants, Who Had Not Been Receiving Corticosteroids for ≥ 12 Weeks, Achieving Clinical Remission at Week 40 of Study APD334-308 Among Participants Receiving Corticosteroids at C5041015 (APD334-302) Study Entry | 7.1 | 25.0 |
Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \[\>=\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease. A subject with sustained clinical remission is defined as someone who achieved clinical remission at both Week 12 of APD334-302 and Week 40 of APD334-308.
| Percentage of participants | Placebo Comparator: Placebo | Experimental: Etrasimod 2 mg |
|---|---|---|
| Percentage of Participants Achieving Sustained Clinical Remission | 0 | 7.1 |
Collected over All-cause mortality, non-serious treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) were collected during the 40-week continuous treatment period, followed by a 4-week follow-up period up to Week 44 of C5041013 (APD334-308).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Comparator: Placebo | 0/14 (0%) | 1/14 (7.1%) | 8/14 (57.1%) |
| Experimental: Etrasimod 2 mg | 0/28 (0%) | 1/28 (3.6%) | 16/28 (57.1%) |
| Event | Placebo Comparator: Placebo | Experimental: Etrasimod 2 mg |
|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 1/14 | 0/28 |
| COVID-19Infections and infestations | 0/14 | 1/28 |
| Event | Placebo Comparator: Placebo | Experimental: Etrasimod 2 mg |
|---|---|---|
| PyrexiaGeneral disorders | 2/14 | 3/28 |
| HeadacheNervous system disorders | 2/14 | 4/28 |
| MalaiseGeneral disorders | 0/14 | 3/28 |
| Colitis ulcerativeGastrointestinal disorders | 1/14 | 2/28 |
| StomatitisGastrointestinal disorders | 1/14 | 0/28 |
| Vaccination site painGeneral disorders | 0/14 | 2/28 |
| Infected dermal cystInfections and infestations | 1/14 | 0/28 |
| SinusitisInfections and infestations | 1/14 | 0/28 |
| TonsillitisInfections and infestations | 1/14 | 0/28 |
| Cervicobrachial syndromeNervous system disorders | 1/14 | 0/28 |
Full Analysis Set: All randomized participants who received at least 1 dose of study intervention.
| Age, Continuous(Years) | Placebo Comparator: Placebo | Experimental: Etrasimod 2 mg | Total |
|---|---|---|---|
| Mean | 44.2 ± 14.12 | 43.9 ± 14.29 | 44.0 ± 14.06 |
| Sex: Female, Male(Participants) | Placebo Comparator: Placebo | Experimental: Etrasimod 2 mg | Total |
|---|---|---|---|
| Female | 7 | 10 | 17 |
| Male | 7 | 18 | 25 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Comparator: Placebo | Experimental: Etrasimod 2 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 14 | 28 | 42 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo Comparator: Placebo | Experimental: Etrasimod 2 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 14 | 28 | 42 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Dec 2020 to primary completion in Aug 2022, 19 months.
Results were first posted in Oct 2023, 1 year 2 months after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 19 months is below that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etrasimod